EAM
TGTX icon

Exome Asset Management’s TG Therapeutics TGTX Stock Holding History

Exome Asset Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.06M Buy
+164,915
New +$6.75M 5.59% 3
2024
Q4 		– Sell
-207,627
Closed -$4.86M – 79
2024
Q3 		$4.86M Sell
207,627
-43,973
-17% -$960K 3.28% 5
2024
Q2 		$4.48M Buy
251,600
+21,300
+9% +$340K 3.99% 4
2024
Q1 		$3.5M Buy
230,300
+27,000
+13% +$430K 3% 6
2023
Q4 		$3.47M Buy
+203,300
New +$2.36M 3.43% 6

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Exome Asset Management's TGTX Position: Q2 2026 in Review

Exome Asset Management opened a new position in TG Therapeutics (TGTX) in Q2 2026: 164,915 shares worth $9.06M. The stake represents 5.59% of the portfolio and ranks #3 among its holdings. This is a return to the name: Exome Asset Management previously reported a position in TGTX as recently as Q3 2024.

Exome Asset Management first reported a position in TGTX in Q4 2023 and has held it in 5 quarters since. 429 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Exome Asset Management held 164,915 shares of TG Therapeutics worth $9.06M as of Q2 2026.
  • TG Therapeutics was a new Exome Asset Management position in Q2 2026.
  • TG Therapeutics made up 5.59% of Exome Asset Management's portfolio in Q2 2026, its #3 holding.
  • Exome Asset Management first reported a position in TG Therapeutics in Q4 2023 and has held it in 5 quarters since.
  • 429 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Exome Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.